Dexcom Inc（DXCM）資訊與事件DXCMDexcom Inc

DexCom CONNECT Trial Results Published, A1C Reduced by 1.6%

DexCom on Wednesday announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine, providing rigorous evidence of the significant benefits of continuous glucose monitoring for adults with Type 2 diabetes not on insulin. Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%, a 0.9% greater A1C reduction compared with routine care.1 Participants using Dexcom G7 also spent approximately five additional hours per day in the glucose target range of 70-180 mg/dL compared with those receiving routine care. "Publication of CONNECT in The New England Journal of Medicine represents a significant moment for the CGM category. Nearly two decades after NEJM last published clinical data on real-time CGM, we now have compelling evidence demonstrating the impact this technology can have for the millions of people with Type 2 diabetes who are not using insulin," said Jake Leach, president and CEO of Dexcom. "Dexcom has spent more than 25 years building the CGM category, and today the evidence is undeniable. We're calling on physicians, payors and healthcare leaders to recognize the meaningful impact CGM can have for this population and help bring the benefits of this technology to millions more people around the world." Shares of DexCom are up 2.4% in pre-market trading.

DexCom Appoints Jereme Sylvain as Chief Operating Officer

DexCom "announced the promotion of Jereme Sylvain to the role of Chief Operating Officer in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcom's global operations and quality teams, driving greater alignment, speed, and accountability across the company as it executes on its vision for growth and commitment to operational excellence. Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021."

Apple Plummets Post-Earnings, Amazon Reports Strong Results

The major averages rallied on the final day of a turbulent month as traders weighed earnings from Apple and Amazon. While Amazon surged on its quarterly beat, Apple suffered a massive decline for their worst post-earnings drop in 13 years. The sharp losses came after the iPhone maker provided a lower-than-expected revenue outlook for Q4 in the face of foreign exchange issues and supply constraints.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Applereported better-than-expected Q3 results butfor Q4 revenue growth amid foreign exchange issues and supply constraintsAmazonreported, with AWS net sales rising to $42.23BChevronreported better-than-expected Q2 earnings and revenue, with the company adding that it reportedExxon MobilreportedRedditreportedand provided upbeat Q3 revenue guidance2. WALL STREET CALLS:Benchmark and BTIGRobloxto Sell following quarterly resultsPiper Sandler and Cantor FitzgeraldReplimuneto Overweight following a postive FDA panel vote supporting RP1 approvalArgusBoston Scientificto HoldGuggenheimQuanta Servicesto BuyBMO CapitalNextpowerto Outperform3. AROUND THE WEB:T-Mobileexecutives have told the company's controlling shareholder, Deutsche Telekom, that they no longer support a proposed $300B merger between the two companies, Semafor reportsNXP Semiconductorsis in discussions to acquire Ambarella, FT reportsChimeis planning to cut about 10% of its workforce, or 150 employees, to capitalize on efficiencies created by AI, Bloomberg reportsTSMCis developing advanced AI chip packaging technology, internally called "EMIB-like," that is said to be similar to Intel'sEmbedded Multi-die Interconnect Bridge technique, The Information saysWSJ said some Teslaexecutives have been instructed by Elon Musk to prepare for a separation of the company's China business in the event of a potential merger with SpaceX, though Musk called the report "absurdly fake news."4. MOVERS:Integer Holdingsincreased afterthat KKRis near a deal to take the company privatenVent Electricwas higher in New York afterand listening additional manufacturing space in MinnesotaNewell Brandsand DexComgained in New York afterGoDaddyfell after, providing guidance for Q3, and narrowing its outlook for FY26BioAge Labsand Monte Rosa Therapeuticswere lower after Novo Nordisk'sZEUS triafor IL 6 inhibition5. EARNINGS/GUIDANCE:AbbVie, cut its EPS guidance for FY26, and provided guidance for Q3RBC Bearings, with EPS and revenue beating consensusColgate-Palmolive, with CEO Noel Wallace commenting on "strong broad-based top- and bottom-line results, despite a difficult operating environment"Eaton, provided guidance for Q3, and raised its outlook for FY26Magnaand raised its outlook for FY26INDEXES:The Dow rose 276.97, or 0.53%, to 52,485.03, the Nasdaq gained 251.68, or 1.00%, to 25,373.85, and the S&P 500 advanced 52.09, or 0.70%, to 7,489.72.